1228244-79-8

Basic information

• Product Name: 1H-Pyrazolo[3,4-b]quinoline, 6-methoxy-3,8-dimethyl-4-[(tetrahydro-1,4-oxazepin-4(5H)-yl)methyl]-
• Synonyms: SCH-1518291;Reaxys ID: 20355486;4-[(6-methoxy-3,8-dimethyl-2H-pyrazolo[3,4-b]quinolin-4-yl)methyl]-1,4-oxazepane
• CAS NO: 1228244-79-8
• Molecular Formula: C19H24N4O2
• Molecular Weight: 340.425
• Mol File: 1228244-79-8.mol

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazolo[3,4-b]quinoline, 6-methoxy-3,8-dimethyl-4-[(tetrahydro-1,4-oxazepin-4(5H)-yl)methyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazolo[3,4-b]quinoline, 6-methoxy-3,8-dimethyl-4-[(tetrahydro-1,4-oxazepin-4(5H)-yl)methyl]-(1228244-79-8)
• EPA Substance Registry System: 1H-Pyrazolo[3,4-b]quinoline, 6-methoxy-3,8-dimethyl-4-[(tetrahydro-1,4-oxazepin-4(5H)-yl)methyl]-(1228244-79-8)

Safety Data

• Hazardous Substances Data: 1228244-79-8(Hazardous Substances Data)

Usage

Pyrazole and quinoline ring structure

The compound has a fused ring system consisting of a pyrazole ring and a quinoline ring.

6-Methoxy substituent

A methoxy group (-OCH3) is attached to the 6th position of the pyrazole ring.

3,8-Dimethyl substituents

Two methyl groups (-CH3) are attached to the 3rd and 8th positions of the quinoline ring.

Tetrahydro-1,4-oxazepin-4(5H)-yl)methyl group

A 5-membered oxazepine ring with a methyl group attached to the 4th position of the quinoline ring.

Diverse pharmacological properties

The presence of multiple functional groups and a complex molecular structure may result in a range of pharmacological activities.

Potential applications in medicinal chemistry

The compound may be useful in the development of new drugs or as a pharmacological tool.

Drug development

It could serve as a lead compound for the development of new therapeutic agents.

Biological research

The compound may be used as a research tool to study the effects of various functional groups on biological systems.

Specific details about properties and potential uses

Further research is needed to determine the exact properties and potential applications of this compound.

In vitro and in vivo testing

The compound would need to undergo various biological assays to evaluate its pharmacological activity and potential side effects.

Structure-activity relationship studies

Investigating the relationship between the compound's structure and its pharmacological properties to optimize its activity and minimize side effects.

Upstream product

• 5638-60-8 1,4-oxazepane 
• 1228245-67-7 C₁₄H₁₃N₃O₂ 
• 40046-28-4 1-isothiocyanato-4-methoxy-2-methylbenzene 
• 1228245-54-2 C₉H₁₃N₃OS 
• 1228245-55-3 C₁₅H₁₉N₃O₃ 
• 1228245-56-4 C₁₃H₁₅N₃O₃ 
• 1228245-53-1 C₁₃H₁₂ClN₃O 
• 1228245-66-6 C₁₄H₁₂N₄O 

Relevant articles and documents

Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia

A series of pyrazoloquinoline analogs have been synthesized and shown to bind to PDE10 with high affinity. From the SAR study and our lead optimization efforts, compounds 16 and 27 were found to possess potent oral antipsychotic activity in the MK-801 induced hyperactive rat model.

SUBSTITUTED PYRAZOLOQUINOLINES AND DERIVATIVES THEREOF

The present invention relates to substituted pyrazoloquinolines of formula I and derivatives thereof, the use of the compounds as phosphodiesterase 10 (PDElO) inhibitors for the treatment of PDElO -modulated disorders, to pharmaceutical compositions comprising the compounds, and to the use of additional substituted pyrazoloquinolines and derivatives thereof for the treatment of PDElO -modulated disorders.